Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00841204
First received: February 10, 2009
Last updated: May 29, 2014
Last verified: March 2013

February 10, 2009
May 29, 2014
February 2009
February 2011   (final data collection date for primary outcome measure)
  • Sulindac Concentration in the Nevi (Moles) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Bioavailability of sulindac and its metabolite in target tissue as measured by post-intervention nevus sulindac and sulindac metabolite concentrations [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00841204 on ClinicalTrials.gov Archive Site
  • Sulindac Effects on Apoptosis in Atypical Nevi [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Association Between Plasma and Target Tissue Drug Levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Sulindac effects on apoptosis in atypical nevi [ Designated as safety issue: No ]
  • Sulindac effects on VEGF expression in atypical nevi [ Designated as safety issue: No ]
  • Association between plasma and target tissue drug levels [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma

This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.

PRIMARY OBJECTIVE:

I. To determine sulindac and metabolite levels in healthy participants with atypical nevi and benign nevus at increased risk for melanoma treated with sulindac versus placebo.

SECONDARY OBJECTIVES:

I. To assess the effects of sulindac on apoptosis in atypical nevi of these participants.

II. To assess the effects of sulindac on VEGF expression in atypical nevi of these participants.

III. To assess sulindac and metabolite levels in plasma and its association with drug levels in the target tissue.

OUTLINE: This is a multicenter study. Participants are randomized to 1 of 2 treatment arms.

ARM I: Participants receive oral sulindac twice daily.

ARM II: Participants receive oral placebo twice daily.

In both arms, treatment continues for 8 weeks in the absence of unacceptable toxicity.

Blood and tissue samples are collected at baseline and/or after completion of study therapy and analyzed for sulindac and metabolite levels via high performance liquid chromatography tandem mass spectrometry; the detection of apoptotic cells via TUNEL assay; and VEGF expression via immunohistochemistry assays.

After completion of study therapy, participants are followed for 2 weeks.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Precancerous Condition
  • Drug: sulindac
    Given orally
    Other Names:
    • Aflodac
    • Algocetil
    • Clinoril
    • SULIN
  • Other: placebo
    Inactive agent
    Other Name: PLCB
  • Other: laboratory biomarker analysis
    Correlative studies
  • Experimental: Arm I
    Participants receive oral sulindac twice daily for 8 weeks
    Interventions:
    • Drug: sulindac
    • Other: laboratory biomarker analysis
  • Placebo Comparator: Arm II
    Participants receive oral placebo twice daily for 8 weeks
    Interventions:
    • Other: placebo
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
February 2011
February 2011   (final data collection date for primary outcome measure)

Criteria:

  • Healthy participants at risk for developing melanoma and meeting the following criteria: must have >= 4 large (>= 5 mm and < 15 mm) atypical nevi and have 1 benign nevus amenable to biopsies
  • No histologically confirmed melanoma on the baseline biopsy
  • No more than 1 prior cutaneous melanoma
  • One prior stage I, IIA, or IIB melanoma allowed provided patients have been off treatment > 3 months
  • Modified dermoscopy score < 4.8
  • Karnofsky performance status 80-100%
  • ANC >= 1,500/mm^3
  • No family history of melanoma involving >= 2 first degree relatives
  • Platelets count >= 100,000/mm^3
  • Total bilirubin =< 2.0 mg/dL
  • AST/ALT =< 2.0 times upper limit of normal
  • Creatinine =< 1.5 mg/dL
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • More than 6 months since prior and no concurrent tanning bed use or other methods to promote sun-tanning
  • Willing to minimize sunlight exposure by applying sunscreen/sunblock or wearing clothing to shield skin during outdoor activity during study participation
  • Willing or able to limit alcohol consumption to less than 3 servings a week during the study period
  • No frequent, chronic or moderate/severe gastrointestinal (GI) complaints
  • Upper GI problems requiring prescription or nonprescription medical remedies for symptoms of heartburn, dyspepsia, nausea, or abdominal pain > once a week on average
  • History of peptic ulcer, occult or gross intestinal bleeding
  • No prior allergic reaction to aspirin (unless subsequent dosing with other NSAIDs has been well tolerated)
  • No history of allergic reaction to lidocaine or xylocaine
  • No history of allergic reaction (e.g., urticaria, asthma, or rhinitis) or gastric intolerance attributed to compounds of similar chemical or biological composition to sulindac
  • No invasive cancer or cancer treatment within the past 5 years, except nonmelanoma skin cancer
  • No immunosuppression by medication or disease, including any of the following: AIDS, oral prednisone, immunosuppressant/immunomodulator (i.e., cyclosporine, chemotherapeutic agent, or biologic therapy)
  • No uncontrolled intercurrent illness
  • No ongoing or active infection
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No psychiatric illness/social situations that would limit compliance with study requirements
  • At least 30 days since prior participation and no concurrent enrollment or planning to enroll in another clinical trial
  • No NSAIDs for more than 5 days per month within the past 3 months and no concurrent non-study NSAIDs, except low dose aspirin (81 mg/day)
  • Willing or able to refrain from herbal medicines, above-standard vitamins, or minerals during study
  • Standard daily multivitamin/mineral supplement (i.e., therapeutic doses of calcium and vitamin D for osteoporosis) allowed
  • No concurrent lithium, phenytoin, or sulfonamides
  • WBC >= 3,000/mm^3
  • No history of bleeding or clotting disorder
  • At least 3 months since prior and no concurrent coumadin or other systemic anticoagulant other than aspirin
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00841204
NCI-2009-01115, NCI-2009-01115, UARIZ-08-0841-04, CDR0000633938, N01CN35158, 08-0841-04, UAZ05-2-10, P30CA023074, N01CN35158
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Hsiao-Hui (Sherry) Chow University of Arizona Health Sciences Center
National Cancer Institute (NCI)
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP